Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback